Drug intelligence / Profile preview

ANG-3522

Development stage: Unknown
Lead developer: Elicio Therapeutics
Modality: Small Molecules

Overview

ANG-3522 is a **small molecule inhibitor** of **cytochrome P450 family 26 subfamily A member 1 (CYP26A1)**, developed by Angion Biomedica. Its **mechanism of action** centers on inhibition of CYP26A1, an enzyme involved in retinoic acid metabolism and homeostasis. By blocking CYP26A1 activity, ANG-3522 may modulate endogenous retinoid activity, potentially affecting processes such as cell differentiation and proliferation. Its main therapeutic targets lie within **skin and musculoskeletal diseases**, and the drug is at the "pending" R&D stage with no active approved indications yet[1].

Targets

CYP26B1 (Cytochrome P450 26B1)CYP26A1 (Cytochrome P450 26A1)

Beyond the preview

Go deeper on ANG-3522.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ANG-3522.

Explore the full profile